Pharma: Clinic Roundup
Friday, June 15, 2012
Teva Pharmaceutical Industries Ltd., of Jerusalem, reported top-line data from the Phase III GALA (Glatiramer Acetate Low-Frequency Administration) trial testing 40 mg/1 ml glatiramer acetate (GA 40 mg/1 ml) injection administered subcutaneously three times a week compared to placebo in relapsing-remitting multiple sclerosis patients.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.